Literature DB >> 29275224

Staging and surgical approaches in gastric cancer: A systematic review.

Natalie Coburn1, Roxanne Cosby2, Laz Klein3, Gregory Knight4, Richard Malthaner5, Joseph Mamazza6, C Dale Mercer7, Jolie Ringash8.   

Abstract

BACKGROUND: Gastric adenocarcinoma accounted for 6.8% of new cancer cases and 8.8% of cancer deaths worldwide in 2012. Although resection is the cornerstone for cure, several aspects of surgical intervention remain controversial or sub-optimally applied at the population level. These include staging, extent of lymph node dissection (LND), optimal requirements of LN assessment, minimum resection margins, surgical technique (laparoscopic vs. open), relationship between surgical volumes and patient outcomes, and resection of stage IV gastric cancer.
METHODS: A systematic review was conducted to inform surgical care.
RESULTS: The evidence included in this systematic review consists of one guideline, seven systematic reviews and 48 primary studies.
CONCLUSIONS: All patients should be discussed at a multidisciplinary team meeting and a staging CT of the chest and abdomen should always be performed. Diagnostic laparoscopy should be performed in patients at risk for stage IV disease. A D2 LND is preferred for curative-intent resection in advanced non-metastatic gastric cancer. At least 16 LNs should be assessed for adequate staging of curative-resected gastric cancer. Gastric cancer surgery should aim to achieve an RO resection margin. In the metastatic setting, surgery should only be considered for palliation of symptoms. Patients should be referred to higher volume centres, and those with adequate support to manage potential complications. Laparoscopic resections should be performed to the same standards as open resections.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Gastric adenocarcinoma; Laparoscopic surgery; Lymph node dissection; Staging; Surgical margins; Surgical volumes

Mesh:

Year:  2017        PMID: 29275224     DOI: 10.1016/j.ctrv.2017.12.006

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  41 in total

Review 1.  Predictive value of preoperative handgrip strength on postoperative outcomes in patients with gastrointestinal tumors: a systematic review and meta-analysis.

Authors:  Xiaoman Jiang; Xinyi Xu; Lingyu Ding; Hanfei Zhu; Jinling Lu; Kang Zhao; Shuqin Zhu; Qin Xu
Journal:  Support Care Cancer       Date:  2022-03-22       Impact factor: 3.603

2.  rs6426881 in the 3'-UTR of PBX1 is involved in breast and gastric cancers via altering the binding potential of miR-522-3p.

Authors:  Maryam Mohammadi; Ali Salehzadeh; Soheila Talesh Sasani; Alireza Tarang
Journal:  Mol Biol Rep       Date:  2021-10-16       Impact factor: 2.316

Review 3.  [ICG lymph node mapping in cancer surgery of the upper gastrointestinal tract].

Authors:  Dolores Müller; Raphael Stier; Jennifer Straatman; Benjamin Babic; Lars Schiffmann; Jennifer Eckhoff; Thomas Schmidt; Christiane Bruns; Hans F Fuchs
Journal:  Chirurgie (Heidelb)       Date:  2022-06-03

Review 4.  Signaling pathways and therapeutic interventions in gastric cancer.

Authors:  Zi-Ning Lei; Qiu-Xu Teng; Qin Tian; Wei Chen; Yuhao Xie; Kaiming Wu; Qianlin Zeng; Leli Zeng; Yihang Pan; Zhe-Sheng Chen; Yulong He
Journal:  Signal Transduct Target Ther       Date:  2022-10-08

5.  MiR-1179 inhibits the proliferation of gastric cancer cells by targeting HMGB1.

Authors:  Yongsheng Li; Ce Qin
Journal:  Hum Cell       Date:  2019-03-22       Impact factor: 4.174

6.  Comprehensive analysis of the prognostic value of the chemokine-like factor-like MARVEL transmembrane domain-containing family in gastric cancer.

Authors:  Zhikun Liang; Jingwen Xie; Lihong Huang; Yaoyao Huang; Yuwen Zhang; Ruanxin Ma; Zhuoling Zheng; Qinbo Wang; Xiaoyan Li
Journal:  J Gastrointest Oncol       Date:  2021-04

7.  Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501).

Authors:  Masanori Terashima; Yoshiaki Iwasaki; Junki Mizusawa; Hiroshi Katayama; Kenichi Nakamura; Hitoshi Katai; Takaki Yoshikawa; Yuichi Ito; Masahide Kaji; Yutaka Kimura; Motohiro Hirao; Makoto Yamada; Akira Kurita; Masakazu Takagi; Narikazu Boku; Takeshi Sano; Mitsuru Sasako
Journal:  Gastric Cancer       Date:  2019-03-02       Impact factor: 7.701

8.  Influencing Factors and Effects of Treatment on Quality of Life in Patients With Gastric Cancer-A Systematic Review.

Authors:  Sophia Kristina Rupp; Andreas Stengel
Journal:  Front Psychiatry       Date:  2021-07-01       Impact factor: 4.157

9.  A novel strategy to identify candidate diagnostic and prognostic biomarkers for gastric cancer.

Authors:  Lei Liu; Honglin Pang; Qiao He; Biran Pan; Xiaobin Sun; Jing Shan; Liping Wu; Kaiwen Wu; Xue Yao; Yuanbiao Guo
Journal:  Cancer Cell Int       Date:  2021-07-02       Impact factor: 5.722

10.  Immune-Related Nine-MicroRNA Signature for Predicting the Prognosis of Gastric Cancer.

Authors:  Jingxuan Xu; Jian Wen; Shuangquan Li; Xian Shen; Tao You; Yingpeng Huang; Chongyong Xu; Yaping Zhao
Journal:  Front Genet       Date:  2021-07-05       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.